Core Viewpoint - Regeneron Pharmaceuticals, Inc. is set to report its third quarter 2025 financial and operating results on October 28, 2025, before the U.S. financial markets open [1] Group 1: Financial Reporting - The third quarter 2025 financial results will be announced before the market opens on October 28, 2025 [1] - A conference call and webcast will take place at 8:30 AM Eastern Time on the same day [1] Group 2: Conference Call Information - Participants can access the conference call live via webcast on Regeneron's 'Investors and Media' page [2] - Telephone participants must register in advance to receive a confirmation email with details on how to join the call [2] - A replay and transcript of the conference call will be available on the company's website for at least 30 days [2] Group 3: Company Overview - Regeneron is a leading biotechnology company focused on developing life-transforming medicines for serious diseases [3] - The company is known for its ability to translate scientific research into approved treatments and has a robust pipeline of product candidates [3] - Regeneron's medicines target a wide range of conditions, including eye diseases, cancer, and rare diseases [3] Group 4: Technological Advancements - Regeneron utilizes proprietary technologies like VelociSuite to develop optimized fully human antibodies and bispecific antibodies [4] - The company leverages data from the Regeneron Genetics Center to identify innovative treatment targets [4]

Core Viewpoint - Regeneron Pharmaceuticals, Inc. will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, at 7:00 a.m. ET [1] Company Overview - Regeneron is a leading biotechnology company focused on inventing, developing, and commercializing life-transforming medicines for serious diseases [3] - The company was founded and is led by physician-scientists, emphasizing its ability to translate scientific research into approved treatments and product candidates [3] - Regeneron's medicines and pipeline target various conditions, including eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases [3] Technological Advancements - Regeneron utilizes proprietary technologies, such as VelociSuite, to produce optimized fully human antibodies and new classes of bispecific antibodies [4] - The company is advancing drug development through data-powered insights from the Regeneron Genetics Center and pioneering genetic medicine platforms [4] - These innovations enable Regeneron to identify innovative targets and complementary approaches for potentially treating or curing diseases [4]

Core Insights - Regeneron Pharmaceuticals, Inc. will report its second quarter 2025 financial and operating results on August 1, 2025, before U.S. markets open [1] - A conference call and webcast will be held at 8:30 AM Eastern Time on the same day [1][2] Company Overview - Regeneron is a leading biotechnology company focused on inventing, developing, and commercializing life-transforming medicines for serious diseases [3] - The company has a strong pipeline of approved treatments and product candidates, primarily developed in-house, targeting various conditions including eye diseases, cancer, and rare diseases [3] Technological Advancements - Regeneron utilizes proprietary technologies like VelociSuite to produce optimized fully human antibodies and bispecific antibodies [4] - The company leverages data-powered insights from the Regeneron Genetics Center to identify innovative treatment targets and approaches [4]

Core Viewpoint - Regeneron Pharmaceuticals has successfully bid for the assets of 23andMe Holding Co. for $256 million, aiming to enhance its leadership in genetics-guided research and drug development, pending bankruptcy court and regulatory approvals [1][2][3] Group 1: Acquisition Details - The planned acquisition includes 23andMe's Personal Genome Service, Total Health and Research Services, and Biobank assets, with the transaction expected to close in Q3 2025 [1] - Regeneron will operate 23andMe as a wholly owned subsidiary, continuing its consumer genomics services while excluding the Lemonaid Health business from the purchase [3][4] Group 2: Commitment to Data Privacy - Regeneron emphasizes its commitment to the privacy and ethical use of 23andMe's customer data, planning to work with an independent Customer Privacy Ombudsman to ensure compliance with privacy policies and laws [2][3] - The company has a proven track record in large-scale data management, having linked deidentified DNA sequences from nearly three million participants to electronic health records [2][3] Group 3: Strategic Vision - Regeneron aims to leverage its expertise in genetic research to support 23andMe's mission of helping individuals understand their DNA and improve personal health [2][3] - The acquisition aligns with Regeneron's broader strategy to utilize genetics research for advancing medical treatments and improving societal health outcomes [2][3][4]

Core Insights - Regeneron Pharmaceuticals, Inc. will report its first quarter 2025 financial and operating results on April 29, 2025, before U.S. markets open [1] - A conference call and webcast will be held at 8:30 AM Eastern Time on the same day [1] Company Overview - Regeneron is a leading biotechnology company focused on inventing, developing, and commercializing medicines for serious diseases [3] - The company was founded and is led by physician-scientists, emphasizing a strong connection between scientific research and medical application [3] - Regeneron's product pipeline targets various conditions, including eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases [3] Technological Advancements - Regeneron utilizes proprietary technologies like VelociSuite to produce optimized fully human antibodies and new classes of bispecific antibodies [4] - The company leverages data-powered insights from the Regeneron Genetics Center and pioneering genetic medicine platforms to identify innovative treatment targets [4]